J.P. Morgan Life Sciences Private Capital has named Bruce N. Rogers, Ph.D., as a Venture Partner. Dr. Rogers brings extensive experience in drug discovery and development, having led significant roles at Morphic Therapeutic and Pfizer. His expertise in medicinal chemistry and neuroscience will help J.P. Morgan support and grow innovative life sciences companies. This appointment signals J.P. Morgan’s commitment to advancing biotech ventures and expanding its life sciences investment platform.
Kailera Therapeutics recently closed at $18.51, down 2.5% for the week and 28.8% since its April IPO. The clinical-stage company, with no product revenue, holds $1.17 billion in cash and has a runway into mid-2028. Its lead drug, ribupatide, is in gl...
Packaged food stocks have significantly underperformed pharmaceutical stocks over the past year, driven largely by concerns over GLP-1 weight-loss drugs impacting food demand. While Eli Lilly's stock soared 74%, many food companies like Campbell's an...
Three major large-cap growth ETFs—Schwab SCHG, Vanguard VUG, and Invesco QQQ—offer different approaches to capturing growth, especially in AI and tech sectors. QQQ, tracking the Nasdaq-100, outperformed with a 10-year return of about 513%, benefiting...
